Alvircept sudotox is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Alvircept sudotox inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis[1][2][3].
Amlitelimab (150 μg/mL) inhibits proliferation of human CD3 T cells[3].
Amlitelimab (150 μg/mL) 抑制人 CD3 T 细胞的增殖[3]。
[1]. Ana Maria LÉ, et al. OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis-Focus on Rocatinlimab and Amlitelimab. Pharmaceutics 2022, 14(12), 2753.
[2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healt Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132.
[3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085.